Group 1 - The board of directors of China National Offshore Oil Corporation (CNOOC) held its sixth meeting of 2025 on May 12, 2025, via written resolution, with all 8 directors present, confirming the legality and validity of the meeting [2][4] - The board approved the proposal regarding changes in the composition of independent non-executive directors and board committees, which was reviewed and submitted by the nomination committee [3][4] - The board also approved the remuneration for independent non-executive director Qiu Zhizhong, who will serve as the chairman of the remuneration committee, and the remuneration for Chen Zeming, pending approval at the 2024 annual general meeting [6][7] Group 2 - The board recommended the re-election of Zhou Xinhai, Wang Dehua, Yan Hongtao, and Mu Xiuping as executive and non-executive directors at the 2024 annual general meeting, with all proposals receiving unanimous support [8][11][14][17] - The board approved a proposal to amend the company's articles of association and rules for general meetings, which will be submitted for approval at the 2024 annual general meeting [20][21] - The board also approved the proposal to convene the 2024 annual general meeting, with details to be announced later [23][24] Group 3 - The board announced the resignation of independent non-executive director Zhao Chongkang, effective at the end of the 2024 annual general meeting, and expressed gratitude for his contributions [30][31] - The board proposed the appointment of Chen Zeming as an independent non-executive director, subject to shareholder approval at the 2024 annual general meeting, with a proposed annual remuneration of HKD 950,000 [32][34] - Changes in the composition of board committees were also announced, with Qiu Zhizhong appointed as chairman of the remuneration committee and Li Shuxian as a member of the nomination committee [36] Group 4 - The board approved amendments to the company's articles of association and rules for general meetings to reflect recent regulatory changes and enhance electronic communication and voting [39][40]

比特币失守101000美元/枚，日内跌超3%。 ...

蚂蚁集团或将对"印度支付宝"Paytm减持大约4%。（PTI） ...

智通财经APP讯，大成糖业(03889)发布公告，孔先生、王先生及华生(统称"主要股东")已通知本公司， 于2025年5月12日，主要股东(各自作为授出人)与高健行先生(高先生)(作为承授人)已订立认购期权协议 (认购期权协议)，主要股东同意向高先生授出本金总额为人民币2700万元的第二批可换股债券的认购期 权(认购期权)。根据第二批可换股债券的条款及条件，本金金额为人民币2700万元的第二批可换股债券 可按每股转换股份0.1港元的初始转换价转换为转换股份，汇率为中国人民银行于转换日期公布的汇 率。为作说明用途，根据本公告日期中国人民银行公布的0.10港元兑人民币0.92639元汇率，经授出认购 期权的本金金额为人民币2700万元的第二批可换股债券可于悉数兑换时转换为不多于2.91亿股转换股 份。 认购期权可由高先生分为五个批次行使(若其选择行使)，本金金额分别为人民币600万元、人民币600万 元、人民币600万元、人民币600万元及人民币300万元。为行使认购期权，高先生须就每批认购期权向 主要股东支付认购期权协议所载较第二批可换股债券相关批次的相关本金金额有溢价的行使价。除非订 约方另行书面协定，所有五 ...

和铂医药-B回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.05.12 | 120.00 | 8.580 | 7.960 | 976.04 | | 2025.05.09 | 18.80 | 8.700 | 8.450 | 161.13 | | 2025.05.08 | 50.00 | 8.390 | 8.190 | 418.15 | | 2025.05.07 | 130.00 | 8.620 | 8.030 | 1067.48 | | 2025.05.06 | 40.00 | 8.790 | 8.530 | 345.81 | | 2025.04.30 | 27.00 | 8.590 | 8.540 | 231.56 | | 2025.04.23 | 40.00 | 7.920 | 7.840 | 315.90 | | 2025.04.17 | 28.90 | 7.350 | 7.180 | 209.13 | | 2025.04.16 | 75.00 | 7.350 ...

Summary of Key Points Core Viewpoint - AIA Group has been actively repurchasing its shares, indicating a strong confidence in its stock value and a commitment to returning capital to shareholders [2][3]. Share Buyback Details - On May 12, AIA repurchased 2 million shares at a price range of HKD 62.050 to HKD 63.700, totaling HKD 125 million [2]. - The stock closed at HKD 63.200 on the same day, reflecting a 2.68% increase with a total trading volume of HKD 20.50 billion [2]. - Since May 8, the company has conducted buybacks for three consecutive days, acquiring a total of 8.5 million shares for a cumulative amount of HKD 524 million, with the stock rising by 2.35% during this period [2]. - Year-to-date, AIA has executed 40 buybacks, totaling 152 million shares and an aggregate buyback amount of HKD 8.21 billion [2]. Historical Buyback Data - The buyback details include various dates, share quantities, highest and lowest prices, and total amounts spent, showcasing a consistent strategy to enhance shareholder value [3]. - For instance, on May 9, 150,000 shares were repurchased at a maximum price of HKD 61.750, costing HKD 92.19 million [3]. - The buyback activity has been frequent, with significant amounts spent on shares at various price points throughout the year, indicating a proactive approach to managing capital and stock performance [3].

Core Points - The Chuanghua Trading Service CSI Hong Kong-Shanghai-Shenzhen 300 Index (CES300) increased by 1.85% to 4772.41 points, with a trading volume of 394.119 billion yuan [1] - The CES300 Index has risen by 7.90% in the past month, 4.07% in the last three months, and 5.80% year-to-date [1] - The index is designed to reflect the overall performance of eligible securities under the "Shanghai-Hong Kong Stock Connect" and "Shenzhen-Hong Kong Stock Connect" programs [1] Index Composition - The top ten holdings of the CES300 Index include Tencent Holdings (8.59%), Alibaba-W (6.4%), HSBC Holdings (4.14%), Kweichow Moutai (2.78%), Xiaomi Group-W (2.26%), Meituan-W (2.25%), China Construction Bank (2.07%), CATL (1.88%), AIA Group (1.75%), and Ping An Insurance (1.56%) [2] - The market share of the CES300 Index holdings is 51.96% from the Hong Kong Stock Exchange, 29.45% from the Shanghai Stock Exchange, and 18.60% from the Shenzhen Stock Exchange [2] - The industry composition of the CES300 Index includes Financials (29.21%), Consumer Discretionary (17.38%), Communication Services (13.28%), Industrials (9.18%), Information Technology (8.59%), Consumer Staples (6.76%), Health Care (4.29%), Materials (3.50%), Utilities (3.10%), Energy (2.86%), and Real Estate (1.85%) [2] Fund Tracking - Public funds tracking the CES300 include Dachen Chuanghua Hong Kong-Shanghai-Shenzhen 300C and Dachen Chuanghua Hong Kong-Shanghai-Shenzhen 300A [3]

Group 1: Store Expansion - Brands continue to expand their store presence post-holiday, with Luckin Coffee opening 91 new stores and Tims opening 21 new stores in the past week [1] - As of April 30, Luckin Coffee has surpassed 5,400 stores nationwide, while Kenyue Coffee has successfully opened over 1,000 stores and plans to reach 1,500 by the end of 2025 [1] - Kudi has extended its store subsidy policy until December 31, 2028, and introduced new subsidies to lower the entry barriers for franchisees [1] Group 2: International Expansion - Luckin Coffee has opened two stores in New York, named "Luck In Coffee Shop" and "Luckin Coffee 2nd shop," which are currently in the renovation and recruitment phase [2] - Nayuki Tea and Hu Shang Ayi are also opening stores in Flushing, New York, which are in the renovation stage [2] Group 3: Product Innovation - Tea brands are increasingly focusing on healthier product offerings, with Cha Hua Nong launching a new "Green Movement Cup" featuring ingredients like kale and chia seeds [3] - CoCo announced a new product, "Super Dragon Fruit Cup," which is low in calories and emphasizes health benefits [3] - New refreshing products are being introduced as temperatures rise, including a new lime matcha series from Jasmine Milk White and a champagne grape series from Tims [4] Group 4: Financial Performance - Hu Shang Ayi debuted on the Hong Kong Stock Exchange at HKD 190.6 per share, a 68.5% increase from its issue price, with a market capitalization exceeding HKD 20.6 billion [7] - Starbucks reported a revenue of USD 739.7 million for Q2 FY2025, a 5% year-on-year increase, with a total of 7,758 stores [7] - Luckin Coffee's Q1 financial report showed a total net revenue of RMB 8.865 billion, a 41.2% year-on-year increase, with a total of 24,097 stores [7] Group 5: Supply Chain Challenges - The surge in demand from online sales has led to supply chain issues for Kudi, resulting in shortages of essential materials and the need to remove popular products from the menu [8]

据了解，中证港股通创新药指数从港股通范围内选取50只业务涉及创新药研发以及为制药企业提供药物 研究、开发和生产等服务的上市公司证券作为指数样本，以反映港股通范围内创新药上市公司证券的整 体表现。该指数以2017年12月29日为基日，以1000.0点为基点。 从指数持仓来看，中证港股通创新药指数十大权重分别为：信达生物（11.31%）、药明生物 （10.96%）、百济神州（9.29%）、康方生物（9.15%）、石药集团（7.19%）、中国生物制药 （6.94%）、翰森制药（4.18%）、药明康德（3.9%）、再鼎医药（3.88%）、三生制药（3.45%）。 从中证港股通创新药指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证港股通创新药指数持仓样本的行业来看，生物药品占比46.61%、化学药占比30.42%、制药与生 物科技服务占比21.65%、医疗商业与服务占比1.32%。 金融界5月12日消息，上证指数高开高走，中证港股通创新药指数 (港股通创新药，931250)下跌3.3%， 报706.45点，成交额170.18亿元。 数据统计显示，中证港股通创新药指数近一个月上涨16.02%，近三个月上 ...